Skip to main content
INAB logo

IN8bio, Inc.

INABNASDAQHealthcareBiotechnology

$1.11Today:- (-)1Y −42.75%

As of Oct 16, 2026 close

Market cap
$23.07M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.88$2.73
Volume (live)
-
Avg. volume (3M)
44.80K

IN8bio (INAB) Income Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), IN8bio posted a net loss of $19.44M, compared with a net loss of $30.44M a year earlier.

IN8bio Income Statement Analysis

Values in millions USD

Scroll to see more
IN8bio, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.000.000.000.000.000.000.000.00
Cost of Revenue2.500.002.500.000.000.000.100.10
Gross Profit-2.500.00-2.500.000.000.00-0.10-0.10
Operating Expenses
Research & Development10.2116.9616.8314.067.355.382.360.58
Selling, General & Administrative9.6512.6413.5114.467.313.182.711.42
Operating Expenses19.8630.6730.3428.5214.658.565.072.00
Operating Income-19.86-30.44-30.01-28.52-14.65-8.56-5.13-2.00
Other Income/Expense
Interest Income0.420.230.000.000.000.000.000.00
Interest Expense0.000.000.000.000.000.000.000.01
Other Income/Expense0.420.230.330.000.000.000.00-0.08
Income
Income Before Tax-19.44-30.44-30.01-28.52-14.65-8.56-5.13-2.08
Income Tax Expense0.000.000.000.000.000.000.000.00
Net Income-19.44-30.44-30.01-28.52-14.65-8.56-5.13-2.08
Net Income - Continuous Operations-19.44-30.44-30.01-28.52-14.65-8.56-5.13-2.08
Net Income - Discontinued Operations--------
EBITDA-17.36-27.76-28.50-27.42-13.87-8.47-5.04-1.97
EBIT-19.86-29.60-30.34-28.52-14.65-8.56--
Depreciation & Amortization2.501.841.831.100.790.090.100.10
Earnings Per Share
Basic EPS-4.00-17.00-30.00-41.00-44.00-91.00-9.00-4.00
Diluted EPS-4.00-17.00-30.00-41.00-44.00-91.00-9.00-4.00
Basic Shares Outstanding4.371.781.000.700.330.110.650.65
Diluted Shares Outstanding4.371.781.000.700.330.110.650.65

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About IN8bio Financial Statements

Is IN8bio profitable?

No. IN8bio reported a net loss of $19.44M in fiscal 2025. In fiscal 2024 it lost $30.44M.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition